Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
PharmAla Biotech to supply MDMA for Harvard med school clinical trial
PharmAla Biotech Holdings Inc. will supply MDMA for a clinical trial at Harvard Medical School’s McLean Hospital. The company is the only supplier of clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla also plans to attend the CPHI pharmaceutical conference in Milan to meet with potential European distribution partners. Harvard renews its focus on psychedelic research with a $16 million program.
Safer Psychedelic Drugs May Be Coming
Companies like Mindstate Design Labs and Beckley Psytech are developing 'next generation' psychedelics to reduce risks and improve efficacy, aiming to make treatments more palatable to regulators and patients.
MDMA Drug Developers Reprioritize Following Lykos Rejection in PTSD
MDMA shows promise in treating PTSD but faces challenges, including FDA rejection of Lykos' therapy. Some developers reassess strategies, while others focus on improving MDMA's safety profile. Despite concerns over abuse potential, MDMA's therapeutic use gains traction globally, highlighting high unmet need in PTSD treatment.
What should constitute a control condition in psychedelic drug trials?
Psychedelics show promise and perils in treating various conditions, with MDMA-assisted therapy for PTSD and psilocybin for depression showing efficacy, while cases of adverse effects like prolonged mania and psychosis exist. Ketamine and other psychedelics are also explored for chronic pain and PTSD, with mixed results. The role of expectations and placebo effects in psychedelic therapy is highlighted, emphasizing the need for careful study design and patient management.
Critics see drug debate tainted by politicization in B.C. election campaign
NDP Leader David Eby's proposal for involuntary care facilities for severe drug addiction and mental health issues faces criticism from advocates like DJ Larkin, who argue the province lacks sufficient voluntary treatment options. The debate over drug policy in B.C. is marked by politicization and mixed results from various strategies, including decriminalization and safer supply programs. Critics argue involuntary care lacks scientific support and could exacerbate the crisis.
DEA Calls To Increase Production of Psychedelics For Clinical Research
The DEA proposed increasing psilocybin, psilocin, and ibogaine production quotas by 50% for 2025, signaling support for psychedelic research. This follows a growing interest in studying these compounds for mental health treatments, despite their Schedule 1 status. The VA is also increasingly involved in psychedelic-assisted therapy research for veterans.
Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., "A Leader in ..."
Water Tower Research published a report on Cybin, Inc., highlighting its leadership in neuropsychiatric therapeutics, rapid advancement of lead candidates CYB003 and CYB004, and differentiated deuteration technology. Cybin's market valuation is favorable compared to peers, and its well-capitalized status positions it for potential success.
Water Tower Research Publishes Initiation of Coverage
Water Tower Research published an Initiation of Coverage Report on Cybin, Inc., highlighting its status as a leader in novel neuropsychiatric therapeutics. Cybin's focus on innovative treatments for mental health disorders like MDD and GAD, with lead candidates CYB003 and CYB004, positions it favorably compared to peers. The report emphasizes Cybin's rapid pipeline advancement and differentiated solutions, noting its favorable valuation and well-capitalized status.
Hyde man pleads guilty to drug delivery charges
John Raymond Jefferson, II, pleaded guilty to drug trafficking charges and will serve a minimum of 36 months in state prison. Jefferson was caught with a large amount of methamphetamine and other illegal drugs. His attorney requested a continuance on sentencing to argue his eligibility for state Department of Corrections programs.
Sam Altman's Psychedelic Breakthrough: How The OpenAI Visionary Plans To Transform
Sam Altman, co-founder of OpenAI, discusses his transformative psychedelic experiences on the Life in Seven Songs podcast, crediting them with improving his mental health. Altman, now chairman of Journey Colab, aims to develop safe, effective psychedelic therapies for conditions like depression and PTSD, partnering with luxury rehab centers like All Points North. Journey Colab plans to make these therapies accessible to marginalized communities.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath